BioWorld

May 25, 2010

View Archived Issues

Biogen and Abbott Start Phase III Trial of MS Antibody Daclizumab

Biogen Idec Inc. and Abbott kicked off a Phase III trial comparing their anti-IL-2 antibody daclizumab to Biogen's Avonex (interferon beta-1a) in relapsing-remitting multiple sclerosis. (BioWorld Today) Read More

NormOxys Gets $17.5M Series B to Fund Cardio, Cancer Studies

Read More

'Vino' What All Start-ups Want: Fated Partners Linking at C21

Read More

NewCo News: Immunome Harnessing Immune System's Natural Curative Ability

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Stock Movers

Read More

Clinic Roundup

Read More